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ORIGINAL INVESTIGATION
Effect of metformin monotherapy 
on cardiovascular diseases and mortality: a 
retrospective cohort study on Chinese type 2 
diabetes mellitus patients
Colman Siu Cheung Fung*, Eric Yuk Fai Wan†, Carlos King Ho Wong†, Fangfang Jiao† and Anca Ka Chun Chan†
Abstract 
Background: Many factors influence whether the first-line oral anti-diabetic drug, metformin, should be initiated to a 
patient with type 2 diabetes mellitus (T2DM) early in the course of management in addition to lifestyle modifications. 
This study aims to evaluate the net effects of metformin monotherapy (MM) on the all-cause mortality and cardiovas-
cular disease (CVD) events.
Methods: A retrospective 5-year follow-up cohort study was conducted on Chinese adult patients with T2DM and 
without any CVD history under public primary care. Cox proportional hazard regressions were performed to compare 
the risk of all-cause mortality and CVD events (CHD, stroke, heart failure) between patients receiving lifestyle modifica-
tions plus MM (MM groups) and those with lifestyle modifications alone (control groups).
Results: 3400 pairs of matched patients were compared. MM group had an incidence rate of 7.5 deaths and 11.3 
CVD events per 1000 person-years during a median follow-up period of 62.5 months whereas control group had 11.1 
deaths and 16.3 per 1000 person-years during a median follow-up period of 43.5–44.5 months. MM group showed 
a 29.5 and 30–35 % risk reduction of all-cause mortality and CVD events (except heart failure) than control group 
(P < 0.001). MM group was more prone to progress to chronic kidney disease but this was not statistically significant.
Conclusions: Type 2 diabetic patients who were started on metformin monotherapy showed improvement in many 
of the clinical parameters and a reduction in all-cause mortality and CVD events than lifestyle modifications alone. If 
there is no contraindication and if tolerated, diabetic patients should be prescribed with metformin early in the course 
of the diabetic management to minimize their risk of having the cardiovascular events and mortality in the long run.
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Background
Diabetes mellitus (DM) is a major public health issue as 
it is estimated that 1 in 12 people are affected by diabe-
tes in the world [1]. The World Health Organization has 
projected that by 2030, diabetes will be the seventh most 
common cause of death in the world [2]. Good control 
of DM is crucial because DM is closely linked to vari-
ous complications, ranging from different cardiovascular 
diseases (including myocardial infarction, cerebrovascu-
lar diseases, etc.) to microvascular diseases like diabetic 
retinopathy [including sight-threatening diabetic retin-
opathy (STDR)] and diabetic nephropathy [including end 
stage renal failure (ESRF)].
Primary care is experiencing more pressure as the num-
bers of patients with diabetes mellitus increase dramati-
cally. Many type 2 diabetic patients are under the care of 
primary care doctors especially if they are newly diag-
nosed with DM or if their condition is relatively stable. 
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Sometimes, primary care doctors or family physicians have 
a difficult time deciding if they should initiate oral anti-
diabetic (OAD) drugs to patients, as there are many fac-
tors influencing whether a drug should be initiated, despite 
some evidence suggesting that early use of OAD drugs, like 
metformin, is beneficial to the patients in terms of lower-
ing the clinical parameters like haemoglobin A1c (HbA1c), 
or reduction of DM-related complications or mortality [3]. 
Metformin, the only available biguanide amongst the OAD 
drugs, is widely used as the first-line OAD in the man-
agement of diabetic patients because of the longstanding 
evidence of its efficacy and comparatively less side-effects 
like hypoglycaemia than sulphonylurea group of OAD 
drugs [4]. Some studies have even advocated the early use 
of metformin as it was found to delay or prevent the inci-
dence of DM or DM-related complications [5]. However, 
patients may prefer not to start OAD drugs for various 
reasons, including possible side-effects, compliance issues, 
life-long drug therapy etc. These concerns are not limited 
to the Chinese population, but are worldwide [6–8]. One 
of the hypotheses was that since DM was a chronic dis-
ease closely linked to lifestyle (including dietary habit and 
exercise intensity), control of these factors, or the lifestyle 
modifications should be implemented before the use of 
OAD drugs [9–13]. American Diabetic Association Guide-
lines suggested metformin, if not contraindicated and if 
tolerated, is the preferred initial pharmacological agent 
for type 2 DM [14] while the local Hong Kong Reference 
Framework for Diabetes Care for Adults in Primary Care 
Setting 2010 suggested initiating metformin as a mono-
therapy for HbA1c <7.5  % for diabetic patients [15]. In 
obese patients, metformin-based monotherapy reduced 
cardiovascular events compared to patients treated with 
lifestyle modifications alone [16]. Despite the availability 
of these guidelines or reference frameworks, the decision 
to start metformin is complex issue and involves clinical 
judgement. There is still a significant proportion of dia-
betic patients who have not started on any anti-diabetic 
medication [17–19]. To our knowledge, there are no pre-
vious studies on the direct comparison between lifestyle 
modifications alone verses metformin monotherapy (MM) 
in addition to lifestyle modifications on the outcomes of 
Chinese diabetic patients. Thus, this study aims to evaluate 
the net effectiveness of MM on the diabetes-related cardi-
ovascular complications and mortality in Chinese patients 
diagnosed with type 2 diabetes by comparing patients with 
lifestyle modifications alone and patients with lifestyle 
modifications plus MM.
Methods
Study design
This was a retrospective cohort study on patients with 
type 2 diabetes under primary care and the dataset was 
extracted from a large scale local diabetic programme 
[20]. The data were collected from the diabetic patients 
under primary care outpatient clinics managed by the 
Hong Kong Hospital Authority (HA) across the whole 
territory between 1 August 2008 and 31 December 2008. 
The data were made available from a large scale study 
for the evaluation of local diabetic programme [20]. The 
HA is the largest government organization monitoring 
all publically-funded hospitals and outpatient clinics in 
Hong Kong.
Chinese patients aged 18 years or older with a clinical 
diagnosis of type 2 diabetes, no history of Cardiovascu-
lar Diseases (CVD), and receiving care with MM or life-
style modifications in primary care clinics of HA between 
1 August 2008 and 31 December 2008 were included in 
the study. According to British National Formulary, met-
formin was not recommended for use in diabetic patients 
with estimated glomerular filtration rate (eGFR) <30 ml/
min/1.73  m2 [21] and thus patients with eGFR <30  ml/
min/1.73  m2 were excluded in the study. The clinical 
diagnosis of type 2 diabetes was defined with the Inter-
national Classification of Primary Care-2 (ICPC-2) code 
of ‘T90’ through the administrative database of HA and 
the CVD identification was showed in the section below. 
Patients in MM group were defined as patients who 
were prescribed metformin as their sole anti-DM drugs 
at baseline (regardless if it was newly prescribed or con-
tinuation of prescription), and they were excluded if an 
additional anti-DM drug was added or if they switched 
to another class of OAD drug or insulin, or stopped met-
formin within 1  year after the baseline, while patients 
in control group were defined as patients not using any 
of the anti-DM drugs at baseline (regardless if they had 
never been prescribed anti-DM drugs or if they were 
previously prescribed anti-DM drugs but were stopped 
for whatever reasons), and they were excluded if any 
anti-DM drug was added within 1  year after the base-
line. Patients who developed any of the outcome events 
within 1  year after the baseline were also excluded for 
both arms. The baseline dates for MM and control 
groups were defined as the date of first prescription with 
metformin only and the first attendance record in pri-
mary care clinics for DM follow-up, respectively. There 
were no standardized definition or protocol of lifestyle 
modifications in the care plan for diabetic patients in pri-
mary care, however, all diabetic patients in both groups 
received personal lifestyle advice and counselling from 
the attending doctors and the nurses during their usual 
DM follow-up consultation care.
Exposures
Follow-up began at baseline and continued until either 
the anti-diabetic drug was switched or an additional 
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anti-diabetic drug was added, the date of incidence of 
outcome, all-cause mortality, a censoring event or last 
contact with any inpatient and outpatient services of 
HA or 31 December 2013. For diabetic patients, who 
are under the care of primary care physicians/family 
doctors in the primary care clinics of HA, there is usu-
ally a 3 to 4 months (12–16 weeks) time period between 
each follow-up consultation, and the patient will be pre-
scribed enough chronic medications (including anti-
diabetic drugs) to last the period between the follow up 
consultations. The doctors seldom write a prescription 
that provides medication for a period of over 120  days. 
For diabetic patients, who do not need any chronic 
medications, the period between the follow up consulta-
tions may be longer but will not be more than 6 months 
(180 days). Thus, the censoring events were no drug pre-
scription record for 121 days and no attendance record in 
primary care clinics of HA for 181 days, for MM group 
and control group, respectively.
Outcomes: cardiovascular and renal events and mortality
The outcomes of interest were the following six events: 
(1) CVD event with any one of the following diagnoses: 
(i) coronary heart disease (CHD), (ii) stroke, or (iii) heart 
failure, (2) CHD, (3) stroke, (4) heart failure, (5) all-cause 
mortality and (6) severe chronic kidney disease (CKD). 
The comorbidities were identified by the diagnosis cod-
ing system of ICPC-2 and International Classification 
of Diseases, Ninth Edition, Clinical Modification (ICD-
9-CM). Hong Kong has a highly subsidized public health 
care therefore the HA serves the majority of patients with 
chronic disease, such as those with DM, providing 90 % 
of in-patient service and covering around 86  % of the 
total hospital admissions in the whole territory [22, 23]. 
Most of these patients’ event incidence were captured by 
the HA central database.
The time of CHD including ischaemic heart disease, 
myocardial infarction, coronary death and sudden death 
was taken as the earliest date of diagnosis with ICPC-2 of 
K74 to K76 or ICD-9-CM of 410.x, 411.x to 414.x, 798.x. 
The time of heart failure was taken as the earliest date of 
diagnosis with ICPC-2 of K77 or ICD-9-CM of 428.x. The 
time of stroke including fatal and non-fatal was taken as 
the earliest date of diagnosis with ICPC-2 of K89 to K91 
or ICD-9-CM of 430.x to 438.x. All-cause mortality were 
determined using the Hong Kong Death Registry popu-
lation data. Severe CKD was defined as eGFR <30  ml/
min/1.73 m2.
Baseline covariates
The baseline covariates included patient’s socio-demo-
graphics, clinical parameters, disease characteristics and 
treatment modalities. Socio-demographics of patients 
included age, gender, smoking status, drinking habit and 
education level. Clinical parameters comprised body mass 
index (BMI), HbA1c, systolic and diastolic blood pres-
sure (SBP & DBP), lipid profile [low-density lipoprotein-
cholesterol (LDL-C) and total cholesterol to high-density 
lipoprotein-cholesterol (TC/HDL-C) ratio and triglycer-
ide (TG)]. Disease characteristics included self-reported 
duration of diabetes mellitus (<5  years; 5–10  years and 
>10  years) and hypertension which was defined as the 
clinical diagnosis with ICPC-2 code of “K86” or “K87”. The 
stage of CKD at baseline was classified according to the 
eGFR (Stage 1: eGFR ≥90 ml/min/1.73 m2; Stage 2: eGFR 
≥60  ml/min/1.73  m2 and <90  ml/min/1.73  m2; Stage 3: 
eGFR ≥30  ml/min/1.73  m2 and <60  ml/min/1.73  m2). 
Treatment modalities included the baseline use of anti-
hypertensive drug and lipid-lowering agent. All labora-
tory assays were performed in accredited laboratories by 
the College of American Pathologists, the Hong Kong 
Accreditation Service or the National Association of Test-
ing Authorities, Australia. The record of all risk factors 
closest to baseline for each patient was used.
Data analysis
Descriptive statistics were used to summarize the base-
line characteristics of demographic and clinical param-
eters, disease characteristics and treatment modalities. 
Differences in baseline characteristics between MM and 
control groups were tested using independent t tests for 
continuous variables or Chi-square tests for categorical 
variables. The change in clinical parameters including 
HbA1c, SBP, DBP, LDL-C, TC/HDL-C ratio, TG and BMI 
after baseline between MM group and control group 
were examined using independent t tests and the change 
in stage of CKD after baseline between MM group and 
control group was evaluated using Chi-square tests.
The incidence rate of CVD was estimated by an exact 
95 % confidence interval (CI) based on a Poisson distri-
bution [24]. Kaplan–Meier survival curves were reported 
and the survival rate differences between groups were 
compared using the log-rank test. Multivariable Cox pro-
portional hazards regression accounting for all baseline 
covariates was used to evaluate the effect of MM group 
comparing with control group on the outcomes. Haz-
ard ratio (HR) and its 95  % confidence intervals were 
reported for each variable in the regression models. The 
proportional hazards assumption was assessed by exam-
ining plots of the scaled Schoenfeld residuals against time 
for the predictors. Presence of multi-collinearity was also 
checked by examining the variance inflation factor. The 
accuracy of the models was evaluated using Harrell’s dis-
crimination C-index, ranging from zero to one. A value 
of 0.5 indicates no predictive discrimination, and values 
of 0 or 1.0 indicate perfect separation of patients [25].
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The analysis was repeated on the cohort using pro-
pensity score matching analysis. The aim of propensity 
score matching analysis was to select patients from MM 
and control groups with similar baseline characteristics. 
The propensity score modelled the probability of met-
formin using multivariable logistic regression adjusted 
by all baseline covariates. The propensity score mapping 
was made using a one-to-one matching with the nearest 
neighbour, within 0.001 caliper and without replacement 
approach. Moreover, two separate sensitivity analyses 
were performed by (1) considering patients with the 
exclusion of outcome events occurring within 1 year after 
study began; and (2) using intention-to-treat approach 
with patients staying in the original group regardless of 
treatment continuation, switching or titration and using 
“last contact” instead of “censoring events” as the end of 
follow-up.
All significance tests were two-tailed and those with a 
p value less than 0.05 were considered statistically sig-
nificant. All statistical analyses were performed using 
STATA Version 13.0.
Collection and analyses of the data in this study was 
ethically approved by all local Institutional Review Board 
(the University of Hong Kong/Hospital Authority Hong 
Kong West (UW 10-369), Hong Kong East (HKEC-2010-
093), Kowloon East and Kowloon Central (KC/KE-10-
0210/ER-3), Kowloon West (KW/EX/10-317 (34-04)), 
New Territories East (CRE-2010.543), and New Territo-
ries West clusters (NTWC/CREC/1091/12)) and clinical 
trial registry (NCT02034695, ClinicalTrials.gov).
Results
The flow of diabetic subjects in the study was summa-
rized in Fig. 1. Originally, there were 25,128 (50.8 %) and 
24,350 (49.2 %) eligible Chinese patients in MM and con-
trol group under the primary care of HA across the whole 
territory between 1 August 2008 and 31 December 2008, 
respectively. With the exclusion of those subjects whose 
management plan changed within 1  year from baseline 
(e.g. adding or switch to another class of anti-diabetic 
drug) and incomplete data of baseline covariates, sub-
jects remaining in MM and control groups were 7493 and 
3800 respectively. Finally, 3400 subjects from each group 
were matched with each other using propensity score 
matching regarding to all baseline characteristics.
Table  1 displays the baseline characteristics between 
MM and control groups before and after propensity 
score matching. In general, MM group was younger and 
had a larger proportion of smokers than control group. 
Also, most of the clinical characteristics between the 
two groups were significantly different. MM group had 
significantly higher HbA1c, triglyceride, BMI and longer 
duration of DM and larger proportion of subjects with 
usage of lipid-lowering agents. On the other hand, con-
trol group had higher SBP, LDL-C, TC/HDL-C ratio, and 
had a larger proportion of subjects with hypertension, 
usage of anti-hypertensive drugs, and Stage 2 or above in 
CKD staging. After propensity score matching, the two 
matched groups showed no difference in terms of base-
line characteristics.
Table  2 compares the clinical parameters between 
MM and control groups in the full and propensity 
score-matched cohorts. MM group showed significant 
improvement in HbA1c, SBP, DBP, LDL-C, TC/HDL-C, 
and BMI when compared to control group in matched 
cohort, with the addition of TG lowering in full cohort. 
Table  3 compares the change in CKD staging, with the 
“post” reading taken as on or before the date of last fol-
low-up, between MM and control groups, and patients in 
MM group were more likely to progress from lower CKD 
stage to higher CKD stage compared with control group.
Table 4 and Fig. 2 show the number and incidence rates 
of all-cause mortality and CVD events for the two cohorts 
together with the Kaplan–Meier survival curves. MM 
group had lower incidence rates in all-cause mortality 
and CVD events than control group and were obtained 
in both full cohort and propensity score-matched cohort. 
Under the propensity score-matched cohort, the median 
follow-up period for MM group was longer (62.5 months) 
than the control group (43.5–44.5  months). MM group 
had an incidence rate of 7.5 deaths per 1000 person-years 
in a median follow-up period of 62.5  months whereas 
control group had 11.1 deaths per 1000 person-years in a 
median follow-up period of 44.5 months. Similarly, MM 
group had a CVD incidence rate of 11.3 per 1000 per-
son-years in a median follow-up period of 62.5  months 
whereas control group had a CVD incidence rate of 16.2 
per 1000 person-years in a median follow-up period of 
43.5 months. Further breakdown of the CVD events into 
CHD, stroke and heart failure also showed results in line 
with that of the all-cause mortality and CVD event. How-
ever, more severe CKD incidents were observed in the 
MM group (7.4 per 1000 person-years) than the control 
group (6.9 per 1000 person-years).
Multivariable Cox proportional hazard regressions 
were performed on the dependent variables of all-cause 
mortality, CVD event and severe CKD, and results for 
both full and propensity score-matched cohorts are 
shown in Table 5. The range of variance inflation factors 
was from 1 to 3.21 which indicated absence of multi-
collinearity and the proportional hazard. Random scat-
tered points were observed from the scaled Schoenfeld 
residual plots which satisfied the proportional hazard 
assumption of Cox models. The full cohort and propen-
sity score-matched cohort demonstrated similar results. 
After propensity score matching, there was a 29.5 % risk 
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reduction of all-cause mortality in MM group compared 
to control group and the difference in their survival time 
was highly significant (P  <  0.001) by the log-rank test. 
Moreover, patients in MM group had around 30–35  % 
risk reduction in the incidence of all the CVD events, 
including CHD and stroke except heart failure, when 
compared to the control group. Log-rank test also sug-
gested that there were significant differences (P  <  0.001 
for CVD event and CHD; P = 0.013 for stroke) in the sur-
vival times of all the CVD events between the two groups. 
For heart failure, log-rank test showed significant differ-
ence between the two groups (P = 0.019) but the risk of 
incident heart failure in Cox model showed no significant 
difference between MM and control groups. Moreover, 
the risk of severe CKD was increased by 16.3 % (though 
statistically insignificant) in MM group when compared 
On metformin only Not on metformin
MM group continued with 
metformin alone
(n=19,864)
Incomplete covariates
(n=12,371)
Control group continued without 
Metformin
(n=13,629)
Incomplete 
covariates
(n=9,829)
Metformin Monotherapy (MM) 
group
(n=25,128)
Developed outcome 
event or Change 
involving anti-diabetic 
drug management 
within a year†
(n=5,265)
Control group
(n=24,350)
Developed outcome 
event or Change 
involving anti-diabetic 
drug management 
within a year
(n=10,721)
MM group
Complete covariates: (n=7,493)
Propensity matched*: (n=3,400)
Control group
Complete covariates (n=3,800)
Propensity matched*: (n=3,400)
• Patients with clinical diagnosis of DM (ICPC code: T90)
• Age ≥ 18 years old
• eGFR ≥ 30 ml/min/1.73m2
• Without CVD event 
• Not on combination therapy/insulin/oral anti-diabetic drugs 
(except metformin)
(n=49,478)
Fig. 1 Flow chart of subjects matching and comparison. MM metformin monotherapy, CVD cardiovascular disease
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Table 1 Baseline characteristics between metformin monotherapy and control groups before and after matching
Factor Full cohort with complete case Propensity score-matched cohort
Total 
(N = 11,293)
MM group 
(N = 7493)
Control group 
(N = 3800)
P value Total  
(N = 6800)
MM group 
(N = 3400)
Control group 
(N = 3400)
P value
Socio-demographic (%, n)
 Age (mean  
± SD, n), 
years
62.05 ± 10.83 
(11,293)
61.70 ± 10.75 
(7493)
62.75 ± 10.97 
(3800)
<0.001* 62.57 ± 10.78 
(6800)
62.64 ± 10.58 
(3400)
62.51 ± 10.98 
(3400)
0.621
 Gender 0.728 0.711
  Female 59.51 % (6721) 59.63 % (4468) 59.29 % (2253) 59.31 % (4033) 59.09 % (2009) 59.53 % (2024)
  Male 40.49 % (4572) 40.37 % (3025) 40.71 % (1547) 40.69 % (2767) 40.91 % (1391) 40.47 % (1376)
 Smoking status <0.001* 0.878
  Non-smoker 92.69 % (10,468) 91.82 % (6880) 94.42 % (3588) 94.04 % (6395) 94.09 % (3199) 94.00 % (3196)
  Smoker 7.31 % (825) 8.18 % (613) 5.58 % (212) 5.96 % (405) 5.91 % (201) 6.00 % (204)
 Alcohol status 0.990 0.634
  Non-drinker 84.77 % (9573) 84.77 % (6352) 84.76 % (3221) 85.03 % (5782) 85.24 % (2898) 84.82 % (2884)
  Drinker 15.23 % (1720) 15.23 % (1141) 15.24 % (579) 14.97 % (1018) 14.76 % (502) 15.18 % (516)
 Educational 
level
0.235 0.672
  No formal 
education/
primary
60.23 % (6802) 59.84 % (4484) 61.00 % (2318) 61.04 % (4151) 61.29 % (2084) 60.79 % (2067)
  Secondary/
tertiary
39.77 % (4491) 40.16 % (3009) 39.00 % (1482) 38.96 % (2649) 38.71 % (1316) 39.21 % (1333)
Clinical parameters (Mean ± SD)
 HbA1c, % 6.83 ± 0.96 
(11,293)
6.99 ± 1.05 
(7493)
6.52 ± 0.64 
(3800)
<0.001* 6.57 ± 0.64 
(6800)
6.57 ± 0.67 
(3400)
6.58 ± 0.62 
(3400)
0.351
 SBP, mmHg 133.17 ± 16.91 
(11,293)
132.92 ± 17.02 
(7493)
133.67 ± 16.69 
(3800)
0.026* 133.41 ± 16.77 
(6800)
133.28 ± 16.92 
(3400)
133.54 ± 16.62 
(3400)
0.512
 DBP, mmHg 74.94 ± 10.04 
(11,293)
74.98 ± 10.08 
(7493)
74.84 ± 9.98 
(3800)
0.479 74.75 ± 9.97 
(6800)
74.68 ± 10.00 
(3400)
74.83 ± 9.95 
(3400)
0.530
 LDL-C, mmol/L 3.25 ± 0.84 
(11,293)
3.18 ± 0.82 
(7493)
3.40 ± 0.87 
(3800)
<0.001* 3.34 ± 0.84 
(6800)
3.32 ± 0.83 
(3400)
3.35 ± 0.85 
(3400)
0.106
 TC/HDL-C Ratio 4.36 ± 1.26 
(11,293)
4.31 ± 1.13 
(7493)
4.45 ± 1.46 
(3800)
<0.001* 4.39 ± 1.16 
(6800)
4.38 ± 1.13 
(3400)
4.41 ± 1.18 
(3400)
0.327
 Triglyceride, 
mmol/L
1.65 ± 0.89 
(11,293)
1.68 ± 0.91 
(7493)
1.59 ± 0.85 
(3800)
<0.001* 1.60 ± 0.83 
(6800)
1.60 ± 0.78 
(3400)
1.60 ± 0.87 
(3400)
0.914
 BMI, kg/m2 25.63 ± 3.91 
(11,293)
25.69 ± 3.89 
(7493)
25.51 ± 3.94 
(3800)
0.018* 25.59 ± 3.85 
(6800)
25.56 ± 3.72 
(3400)
25.61 ± 3.98 
(3400)
0.665
 Stage of CKD 
(%, n)
<0.001* 0.711
  Stage 1 35.74 % (4036) 37.89 % (2839) 31.50 % (1197) 32.85 % (2234) 32.62 % (1109) 33.09 % (1125)
  Stage 2 55.98 % (6322) 54.16 % (4058) 59.58 % (2264) 58.71 % (3992) 59.15 % (2011) 58.26 % (1981)
  Stage 3 8.28 % (935) 7.95 % (596) 8.92 % (339) 8.44 % (574) 8.24 % (280) 8.65 % (294)
Disease characteristics (%, n)
 Duration of DM <0.001* 0.652
  <5 years 63.91 % (7217) 59.72 % (4475) 72.16 % (2742) 70.03 % (4762) 70.06 % (2382) 70.00 % (2380)
  5–10 years 23.84 % (2692) 26.37 % (1976) 18.84 % (716) 20.50 % (1394) 20.76 % (706) 20.24 % (688)
  >10 years 12.26 % (1384) 13.91 % (1042) 9.00 % (342) 9.47 % (644) 9.18 % (312) 9.76 % (332)
 Hypertension <0.001* 0.669
  No 28.30 % (3196) 31.59 % (2367) 21.82 % (829) 23.81 % (1619) 24.03 % (817) 23.59 % (802)
  Yes 71.70 % (8097) 68.41 % (5126) 78.18 % (2971) 76.19 % (5181) 75.97 % (2583) 76.41 % (2598)
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to control group. This was also in line with the results in 
log-rank test (P = 0.877).
The details of the sensitivity analysis are shown in Addi-
tional file  1: Table  S1 and the corresponding Kaplan–
Meier survival curves are plotted in Additional file  1: 
Fig. S1a, b. If the exclusion of outcome events occurring 
within 1  year after baseline was considered, the results 
were better than the main analysis with 33.4, 27.6, 25.7, 
30.0 and 36.0  % significant risk reduction of all-cause 
mortality, CVD event, CHD, stroke and even heart failure 
in MM group compared to the control group. However, 
the effect of Metformin was reduced if the intention-to-
treat approach was adopted. Although MM group had 
a risk reduction of 10–20 % in all of the outcome events 
except chronic kidney disease compared to the control 
group, only the risk reductions of CVD event and CHD 
reached statistically significance.
Discussions
This article is by far the latest and largest head-to-head 
comparison, between MM and diabetic patients not 
receiving any medications for their DM, on the clinical 
outcomes of Chinese diabetic patients at the primary 
care level. This study showed that diabetic patients who 
were started with MM showed improvement in many 
of the clinical parameters including HbA1c, SBP, DBP, 
LDL-C, TC/HDL-C, and BMI, and a reduction in all-
cause mortality and CVD events when compared to life-
style changes alone. Metformin is recommended as the 
first-line OAD drug worldwide unless contraindicated. 
The most difficult decision for the primary care doc-
tors is to decide if and when the diabetic patient needs 
to start metformin at the early stage of management of 
their diabetes in order to modify the disease course and 
enhance the prognosis. Findings from this study can give 
more light to primary care doctors on making such deci-
sion. It was worthwhile to note that at the baseline, about 
half of our eligible diabetic patients (24,350 out of 49,478) 
were not prescribed any anti-diabetic medications, 
and the number was comparable to that on metformin 
monotherapy (25,128 out of 49,478). The underlying 
reasons are worth exploring. Some patients may want 
to try lifestyle modifications first and to see if there are 
any improvements in their control of DM before using 
medications. Patients’ concern of the side-effects of the 
drugs, drug compliance issues, and lifelong drug ther-
apy are barriers to patients starting metformin. Some 
patients may seek help from alternative medicine or Chi-
nese herbs, which is not uncommon in Chinese commu-
nity as traditional Chinese medicine has its own school 
of theory on DM [26–28]. The financial influence on the 
decision to prescribe metformin in our study population 
was minimal as patients under primary care in the public 
system only needed to pay HKD 45 [USD 5.78] for the 
consultation fee and there was no additional drug fee 
for the metformin. Doctors, on the other hand, may use 
“non-pharmacological” approach of management as an 
incentive to make their patients more adhere to healthier 
lifestyle modifications through diet control and regular 
exercise. Patient may depend on metformin rather than 
diet and exercise if they knew that the medications was 
helping them [29].
Although lifestyle modifications are supposed to be 
harm-free, it is generally a vague concept, and patients 
Table 1 continued
Factor Full cohort with complete case Propensity score-matched cohort
Total 
(N = 11,293)
MM group 
(N = 7493)
Control group 
(N = 3800)
P value Total  
(N = 6800)
MM group 
(N = 3400)
Control group 
(N = 3400)
P value
Treatment modalities (%, n)
 Use of anti-
hypertensive 
drugs
<0.001* 0.956
  No 29.33 % (3312) 31.06 % (2327) 25.92 % (985) 26.41 % (1796) 26.38 % (897) 26.44 % (899)
  Yes 70.67 % (7981) 68.94 % (5166) 74.08 % (2815) 73.59 % (5004) 73.62 % (2503) 73.56 % (2501)
 Use of lipid-
lowering 
agents
0.032* 0.699
  No 95.71 % (10809) 95.42 % (7150) 96.29 % (3659) 96.32 % (6550) 96.41 % (3278) 96.24 % (3272)
  Yes 4.29 % (484) 4.58 % (343) 3.71 % (141) 3.68 % (250) 3.59 % (122) 3.76 % (128)
MM metformin monotherapy, HbA1c haemoglobin A1c, SBP systolic blood pressure, DBP diastolic blood pressure, LDL-C low density lipoprotein—cholesterol, TC Total 
cholesterol, HDL-C high density lipoprotein-cholesterol, BMI body mass index, eGFR estimated glomerular filtration rate, DM diabetes mellitus, CKD chronic kidney 
disease
Stage 1 CKD (eGFR ≥90 ml/min/1.73 m2); Stage 2 CKD (eGFR ≥60 & <90 ml/min/1.73 m2); Stage 3 CKD (eGFR ≥30 & <60 ml/min/1.73 m2)
* Significant with p value < 0.05 by Chi-square test or t test as appropriate
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may not be able to comply closely with these lifestyle 
modifications [30]. Patients who are prescribed met-
formin were usually advised to continue with the lifestyle 
modifications that were relevant to DM. Patients on met-
formin had reduced incidence rate of all-cause mortality, 
CVD events (including CHD, stroke, and heart failure), 
and severe CKD. The longer median follow-up peri-
ods (43.5–44.5 months) for control group than the MM 
group (62.5 months) suggested that control group had a 
higher chance to have a change in their condition (either 
the control of DM or an event) that warrants change of 
their management of DM. When the severity of DM, as 
reflected by HbA1c, and other factors were controlled, 
a patient on metformin had 29.8 % lower risk of having 
all-cause mortality, and 29.6  % lower risk of having any 
of the CVD event when compared to a patient on life-
style modifications alone. These risk reductions may 
be partially attributed by the coherent improvement in 
SBP, DBP, LDL-C, TC/HDL-C, TG and BMI. HbA1c, the 
indicator used to reflect the control of DM in the past 
2–3 months, on the contrary showed an elevation. Nev-
ertheless, the rise in HbA1c was significantly less than 
that of control group. The matched cohort showed that 
MM group had a net less of 0.09 % in HbA1c compared 
to control group during the follow-up period. With refer-
ence to the United Kingdom Prospective Diabetes Study 
(UKPDS), every 1 % reduction in HbA1c was associated 
with reduction in risk of stroke by 12 %, CHD by 9.9 %, 
heart failure by 16  % and all-cause mortality by 14  % 
[31, 32], our study showed that patients in MM group 
may well have a reduction in stroke, CHD, heart failure, 
and all-cause mortality by 30.2, 35.5, 31.2 and 29.5  %, 
respectively, when compared to control group. Met-
formin was suggested to be able to modify LDL-C and 
TG, and may be associated with weight loss [33–35]. In 
this study, patients in MM group also achieved a signifi-
cant weight loss (a significant 0.15 kg/m2 less) when com-
pared to control group, and a significant of 0.29 mmol/L 
drop in LDL-C and 0.02  mmol/L TG. This may explain 
why patients in MM group had a reduced risk for CVD 
despite the absence of HbA1c reduction. The other rea-
son may be the direct protective effects of the heart by 
metformin [36–42]. Metformin was found capable to 
activate AMP-activated protein kinase thus protecting 
human coronary artery endothelial cells against diabetic 
lipoapoptosis in experimental setting [37]. Metformin 
was found to improve glycocalyx barrier properties in 
db/db mice [38], attenuate Ang-II-induced atheromatous 
plaque formation and aortic aneurysm in ApoE(−/−) 
mice [39]. Treatment with metformin significantly atten-
uates neointimal hyperplasia in fructose-induced insulin 
resistant rats [40] and myocardial remodeling and neu-
trophil recruitment after myocardial infarction in rats 
[41]. In addition, metformin monotherapy was associ-
ated with a decreased risk of atrial fibrillations in patients 
with type 2 DM, probably via attenuation of atrial cell 
tachycardia-induced myolysis and oxidative stress [42]. 
The beneficial effects of metformin obtained from these 
studies reinforced our study findings on the cardiovascu-
lar protective effects of metformin use on patients with 
type 2 DM. Some studies also advocated the early use 
of metformin in patients with pre-diabetes, as it could 
potentially postpone the development of DM and reduce 
the associated cardiovascular risk [43–45]. Further stud-
ies are needed to explore the relationship between met-
formin and CVDs.
Although patients on metformin monotherapy was 
at a higher risk of having eGFR <30  ml/min/1.73  m2, 
Patients in MM group were found to be non-inferior in 
risk of severe CKD compared to those in control group. 
However, the breakdown analysis showed that a patient 
on metformin was more prone to progress towards poor 
renal function in the CKD stages (MM group 15.5 % vs 
control group 11.5  %). Caution should be implemented 
when prescribing metformin and renal function should 
be regularly monitored.
In view of the overall significant benefit of metformin 
use early in the course of diabetic patient management, 
Table 3 Comparisons of stage of chronic kidney disease between baseline and post
MM metformin monotherapy, CKD chronic kidney disease, eGFR estimated glomerular filtration rate
Stage 1 CKD (eGFR ≥90 ml/min/1.73 m2); Stage 2 CKD (eGFR ≥60 & <90 ml/min/1.73 m2); Stage 3 CKD (eGFR ≥30 & <60 ml/min/1.73 m2)
Stage 4 CKD (eGFR ≥15 & <30 ml/min/1.73 m2); Stage 5 CKD (eGFR <15 ml/min/1.73 m2)
* Significant with p value <0.05 by Chi-square test
Stage of CKD (%, n/N) Full cohort with complete case Propensity score-matched cohort
MM group Control group P value MM group Control group P value
Stage 1 (baseline) to stage 2 or above (post) 21.98 % (624/2839) 21.72 % (260/1197) 0.856 23.26 % (258/1109) 21.07 % (237/1125) 0.211
Stage 2 (baseline) to stage 3 or above (post) 10.62 % (431/4058) 6.89 % (156/2 264) <0.001* 11.09 % (223/2011) 6.66 % (132/1981) <0.001*
Stage 3 (baseline) to stage 4 or above (post) 10.74 % (64/596) 9.73 % (33/339) 0.629 11.43 % (32/280) 9.18 % (27/294) 0.376
Total 14.93 % (1119/7493) 11.82 % (449/3800) <0.001* 15.09 % (513/3400) 11.65 % (396/3400) <0.001*
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Table 4 Number and incidence rates of all-cause mortality, CVD event and severe chronic kidney disease
MM metformin monotherapy, CVD cardiovascular disease, CHD coronary heart disease, eGFR estimated glomerular filtration rate, DM diabetes mellitus, CI confidence 
interval, CKD chronic kidney disease
a The 95 % CI was constructed based on Poisson distribution
Event Cumulative incidence Incidence rate (cases/1000  
person-years)
Person-years Median follow-up 
periods (months)
No. of event Rate (%) Estimate 95 % CIa
Full cohort (N = 11,293)
 All-cause mortality 397 3.52 8.713 (7.877–9.614) 45,561.5 60.5
 CVD 610 5.40 13.527 (12.474–14.644) 45,095.8 58.5
  CHD 294 2.60 6.482 (5.763–7.267) 45,353.5 59.5
  Stroke 266 2.36 5.865 (5.182–6.614) 45,351.9 59.5
  Heart failure 139 1.23 3.055 (2.569–3.608) 45,493.0 60.5
 Severe CKD 333 2.95 5.266 (4.716–5.864) 63,230.1 60.5
MM group (N = 7493)
 All-cause Mortality 240 3.20 7.591 (6.661–8.615) 31,615.0 62.5
 CVD 382 5.10 12.204 (11.011–13.492) 31,300.8 61.5
  CHD 176 2.35 5.591 (4.796–6.481) 31,477.2 61.5
  Stroke 170 2.27 5.403 (4.621–6.279) 31,466.3 61.5
  Heart failure 85 1.13 2.692 (2.150–3.328) 31,580.7 62.5
 Severe CKD 230 3.07 7.275 (6.365–8.278) 31,615.0 62.5
Control group (N = 3800)
 All-cause Mortality 157 4.13 11.257 (9.565–13.162) 13,946.5 45.5
 CVD 228 6.00 16.528 (14.452–18.818) 13,795.0 44.5
  CHD 118 3.11 8.504 (7.039–10.184) 13,876.3 45
  Stroke 96 2.53 6.914 (5.600–8.443) 13,885.6 44.5
  Heart failure 54 1.42 3.881 (2.916–5.064) 13,912.3 45.5
 Severe CKD 103 2.71 7.385 (6.028–8.957) 13,946.5 45.5
Propensity score-matched cohort (N = 6800)
 All-cause mortality 249 3.66 9.104 (8.009–10.308) 27,349.6 60.5
 CVD 366 5.38 13.527 (12.177–14.987) 27,056.3 58.5
  CHD 183 2.69 6.724 (5.785–7.772) 27,217.4 59.5
  Stroke 162 2.38 5.951 (5.070–6.942) 27,221.0 59.5
  Heart failure 77 1.13 2.821 (2.226–3.525) 27,298.1 60.5
 Severe CKD 197 2.90 7.203 (6.232–8.282) 27,349.6 60.5
MM group (N = 3400)
 All-cause mortality 113 3.32 7.493 (6.175–9.008) 15,081.4 62.5
 CVD 169 4.97 11.330 (9.686–13.173) 14,915.8 62.5
  CHD 81 2.38 5.398 (4.287–6.710) 15,004.7 62.5
  Stroke 76 2.24 5.065 (3.990–6.339) 15,006.4 62.5
  Heart failure 34 1.00 2.257 (1.563–3.154) 15,062.0 62.5
 Severe CKD 112 3.29 7.426 (6.115–8.936) 15,081.4 62.5
Control group (N = 3400)
 All-cause mortality 136 4.00 11.086 (9.301–13.113) 12,268.2 44.5
 CVD 197 5.79 16.227 (14.040–18.658) 12,140.6 43.5
  CHD 102 3.00 8.352 (6.810–10.139) 12,212.8 43.5
  Stroke 86 2.53 7.041 (5.632–8.695) 12,214.6 43.5
  Heart failure 43 1.26 3.514 (2.543–4.734) 12,236.1 43.5
 Severe CKD 85 2.50 6.929 (5.534–8.567) 12,268.2 44.5
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Fig. 2 Kaplan–Meier survival curves of outcomes. MM metformin monotherapy, CVD cardiovascular disease, CHD coronary heart disease, CKD 
chronic kidney disease
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primary care doctors should discuss with their patients 
in details about the early initiation of metformin for their 
long-term management plan of DM. At the same time, 
the role of lifestyle modifications, including DM diet, reg-
ular exercise, and weight control, are equally important 
as patients with chronic disease are now encouraged to 
be more self-empowered or self-enabled when living with 
their chronic diseases [14]. Doctors should also monitor 
their renal function regularly, and be alert if a patient is 
having any metformin-related side-effects, like vitamin 
B12 deficiency presentations [46].
Strengths and limitations of this study
The large number of diabetic patients involved in this 
study and the long period of follow-up helped reflect 
the effect of metformin monotherapy and lifestyle modi-
fications on the outcomes of diabetic patients. The pro-
pensity score-matched cohort controlled many of the 
confounding factors like age of patient, severity of DM at 
baseline, etc. The consistency of most findings from both 
full cohort with complete case and propensity score-
matched cohort analytical approaches strongly suggested 
that use of metformin is comparatively beneficial to dia-
betic patients in terms of their clinical parameters and 
clinical outcomes.
Limitations of the study included, firstly, the incom-
plete data of the baseline covariates. Significant propor-
tions of patients in MM and control groups were dropped 
out from the analysis because they lacked the baseline 
covariates. Although the propensity score matching can 
help to balance the baseline characteristics between the 
MM and control groups, this greatly reduced the sample 
size, especially the MM group (from 7493 to 3400), after 
matching. Secondly, we lacked some fine details on the 
use of metformin, including the change in exact dosage of 
metformin of each individual patient taking it. Drug com-
pliance to metformin could not be assessed in our study. 
The side-effects of metformin and the contraindication to 
metformin had also not been taken into account, but an 
attempt was tried to reveal if metformin was related to 
worsening of renal function by monitoring the eGFR and 
the CKD staging. Further studies can focus on metformin 
monotherapy versus other class of anti-diabetic drugs, 
or the effectiveness of metformin combination therapy 
in the management of diabetic patients. Lastly, our study 
relied on the ICPC-2 and ICD-9-CM diagnosis coding in 
identifying all the outcome events. However, there were 
no prior studies conducted to evaluate the accuracy and 
completeness of these coding methods. Possible misclas-
sification bias may have occurred.
Conclusions
Type 2 diabetic patients who were started on met-
formin monotherapy showed improvement in many 
of the clinical parameters and a reduction in all-
cause mortality and CVD events when compared 
Table 5 Multivariable Cox proportional hazard regression all-cause mortality, CVD event and severe chronic kidney dis-
ease
MM metformin monotherapy, CVD cardiovascular disease, CHD coronary heart disease, eGFR estimated glomerular filtration rate, DM diabetes mellitus, HR hazard 
ratio, CI confidence interval
* p value <0.05
a HR >1 indicates greater risk for death
MM group comparing with control group Harrell’s C-statistic
HRa 95 % CI P value
Full cohort (N = 11,293)
 All-cause mortality 0.725 (0.584–0.901) 0.004* 0.806 (0.783–0.828)
 CVD 0.726 (0.609–0.866) <0.001* 0.731 (0.711–0.752)
  CHD 0.670 (0.521–0.862) 0.002* 0.727 (0.698–0.756)
  Stroke 0.750 (0.573–0.982) 0.036* 0.734 (0.704–0.765)
  Heart failure 0.795 (0.551–1.147) 0.221 0.872 (0.844–0.899)
 Chronic kidney disease (eGFR <30 ml/min/1.73 m2) 1.076 (0.838–1.381) 0.565 0.848 (0.827–0.870)
Propensity score-matched cohort (N = 6800)
 All-cause mortality 0.705 (0.547–0.908) 0.007* 0.809 (0.783–0.836)
 CVD 0.684 (0.556–0.842) <0.001* 0.731 (0.705–0.756)
  CHD 0.645 (0.480–0.866) 0.004* 0.720 (0.683–0.758)
  Stroke 0.698 (0.511–0.954) 0.024* 0.754 (0.719–0.790)
  Heart failure 0.688 (0.435–1.086) 0.109 0.865 (0.825–0.906)
 Chronic kidney disease (eGFR <30 ml/min/1.73 m2) 1.163 (0.874–1.549) 0.300 0.854 (0.826–0.881)
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with lifestyle modifications alone. If there is no con-
traindication and if tolerated, diabetic patients should 
be prescribed with metformin early in the course of 
the management plan to minimize their risk of hav-
ing the cardiovascular events and mortality in the 
long run. However, renal function should be regularly 
monitored.
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